MOESM2 of Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1

Additional file 2. Domains/subdomains of PvDBP RII

MOESM3 of Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1

Additional file 3. Spatially-derived nucleotide diversity for PvAMA1 across multiple populations

MOESM5 of Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1

Additional file 5. Spatially-derived nucleotide diversity for PvDBP across multiple populations

MOESM1 of Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1

Additional file 1. Domains/subdomains of PvAMA1

MOESM4 of Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1

Additional file 4. Spatially-derived Tajima’s D for PvAMA1 across multiple populations

MOESM7 of Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1

Additional file 7. Location of statistically significant (p < 0.05) Tajima’s D values on modelled PvAMA1 (a) and PvDBP (b) structures

MOESM11 of Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1

Additional file 11. Table of highly polymorphic residues within PvAMA1

MOESM1 of Maximizing research study effectiveness in malaria elimination settings: a mixed methods study to capture the experiences of field-based staff

Additional file 1: Table S1. Provinces, ODs and HCs visited by the quantitative field team in zones 1 and 2 of the containment project. Table S2. Sociodemographic characteristics of 197 VMW and MMWs

Malaria testing strategies and TPP coverage.

<p>Testing strategies are typically classified as passive and active detection where passive detection concerns symptomatic cases and active detection all infections, symptomatic or not. Passive detection is used for the confirmation of symptomatic suspected cases presenting to the healthcare system where treatment is based on a positive parasitological test (PCD: passive case detection). Active detection is typically divided as reactive and proactive detection where reactive detection consists of the active screening of a set of individuals linked geographically or sociologically to an index case for infection detection and treatment. Proactive detection can either be linked with treatment in focal screen-and-treat (FSAT) or mass screen-and-treat (MSAT) interventions or in location-based testing (<i>e</i>.<i>g</i>. boarder screening) or be independent of treatment in epidemiological surveys. The coverage of each of the three TPPs for <i>P</i>. <i>vivax</i> diagnostic tests, PvA, PvB1 and PvB2, is indicated in relation to these testing strategies. The classification of intervention types is adapted from [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005516#pntd.0005516.ref036" target="_blank">36</a>].</p

Summary of key distinguishing features of TPP PvA, PvB1, and PvB2

<p>Summary of key distinguishing features of TPP PvA, PvB1, and PvB2</p